<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Validated and accurate laboratory testing for" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a crucial"/>
 <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Validated and accurate laboratory testing for Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a crucial part"/>
 <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Validated and accurate laboratory testing for Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) is a crucial part of"/>
 <result pre="Abstract Validated and accurate laboratory testing for Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) is a crucial part of the"/>
 <result pre="is a crucial part of the timely management of Coronavirus" exact="Disease" post="2019 (COVID-19) disease, supporting the clinical decision-making process for"/>
 <result pre="Disease 2019 (COVID-19) disease, supporting the clinical decision-making process for" exact="infection" post="control at the healthcare level and detecting asymptomatic cases."/>
 <result pre="in vitro diagnostic tests RT-qPCR serology immunoassays 1. Introduction Coronavirus" exact="Disease" post="2019 (COVID-19), caused by the novel coronavirus Severe Acute"/>
 <result pre="Introduction Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as"/>
 <result pre="Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV),"/>
 <result pre="Disease 2019 (COVID-19), caused by the novel coronavirus Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV), appeared"/>
 <result pre="2019 (COVID-19), caused by the novel coronavirus Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV), appeared in"/>
 <result pre="the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2," exact="formerly" post="known as 2019-nCoV), appeared in China for the first"/>
 <result pre="COVID-19 pandemic. Johns Hopkins University reported over 7,600,000 cases of" exact="infection" post="and more than 427,000 deaths as of 13 June"/>
 <result pre="a result of this rapidly progressing COVID-19 pandemic and the" exact="limited" post="laboratory-based molecular testing capacities, new point-of-care (POC), scalable rapid"/>
 <result pre="Unreliable and unproved tests may not detect patients with active" exact="infection" post="or may incorrectly indicate COVID-19-negative patients as positive, hampering"/>
 <result pre="present, only molecular quantitative reverse transcription PCR (RT-qPCR) testing of" exact="respiratory" post="tract samples is the recommended method for the identification"/>
 <result pre="available. However, they can be useful in epidemiologic research or" exact="disease" post="surveillance and further evolve as a critical step to"/>
 <result pre="of the utmost importance. As in the case of other" exact="infectious diseases," post="the RT-qPCR method, as well as serological tests, are"/>
 <result pre="time, especially plays a role at the early stages of" exact="viral infection," post="when the virus multiplies quickly, as this technique enables"/>
 <result pre="of the pathogenâ€™s genetic material. A different approach in diagnosing" exact="infection" post="is represented by serological methods, based on detectingâ€&quot;in blood"/>
 <result pre="based on detectingâ€&quot;in blood serumâ€&quot;of antibodies that act specifically against" exact="viral" post="proteins, which are produced in response to SARS-CoV-2. Serological"/>
 <result pre="should not be used as basis for diagnosing, ruling out" exact="infection" post="with SARS-CoV-2, or informing about infection status [6]. The"/>
 <result pre="for diagnosing, ruling out infection with SARS-CoV-2, or informing about" exact="infection" post="status [6]. The relatively quick discovery of the composition"/>
 <result pre="2 (ACE2). The S protein on the surface of the" exact="viral" post="particles and has been reported to be highly immunogenic."/>
 <result pre="of SARS-CoV-2 is responsible for the transcription and replication of" exact="viral" post="RNA, the packaging of the encapsulated genome into virions,"/>
 <result pre="has a substantial immunogenic ability and is abundantly expressed during" exact="viral infection" post="(Figure 1). The S/N proteins are targeted as potential"/>
 <result pre="a substantial immunogenic ability and is abundantly expressed during viral" exact="infection" post="(Figure 1). The S/N proteins are targeted as potential"/>
 <result pre="be carried out as an entirely automated mode within a" exact="short" post="time. Unfortunately, the equipment has not been available for"/>
 <result pre="BioMaxima has invented a test whose main advantages include a" exact="short" post="waiting time; the results can be obtained in a"/>
 <result pre="transported in dry ice. Storing such reagents, even for a" exact="short" post="time, in conditions that deviate from those indicated is"/>
 <result pre="30 min, whereas the fastest current methods that concentrate on" exact="viral" post="RNA give results in 1.5 to 2 h, i.e.,"/>
 <result pre="in recent years, proved to function perfectly in diagnosing multiple" exact="infections" post="(including Hepatitis C Virusâ€&quot;HCV and influenza) [16]. RNA detection"/>
 <result pre="years, proved to function perfectly in diagnosing multiple infections (including" exact="Hepatitis" post="C Virusâ€&quot;HCV and influenza) [16]. RNA detection may be"/>
 <result pre="LAMP starters (comprising six starters in each set/kit) focused on" exact="viral" post="RNA of SARS-CoV-2 in the regions of ORF1ab, S"/>
 <result pre="been applied, which enables the reading of the results of" exact="viral" post="RNA amplification by the naked eye, without the necessity"/>
 <result pre="the sensitivity of the method may be 80 copies of" exact="viral" post="RNA per 1 mL in the sample and single"/>
 <result pre="the use of expensive and time-consuming laboratory processes. Additionally, the" exact="American" post="company Cepheid developed a quick test which, as they"/>
 <result pre="was designed to provide detection of novel coronavirus within a" exact="short" post="period of 45 min, using specimens from a nasopharyngeal"/>
 <result pre="do not necessarily indicate that person has not contracted an" exact="infectious disease," post="as other individual factors also need to be considered,"/>
 <result pre="Moreover, the set/kit does not exclude diseases caused by other" exact="bacterial" post="or viral pathogens. The negative results do not exclude"/>
 <result pre="set/kit does not exclude diseases caused by other bacterial or" exact="viral" post="pathogens. The negative results do not exclude infection and"/>
 <result pre="bacterial or viral pathogens. The negative results do not exclude" exact="infection" post="and should not be the sole basis for patientsâ€™"/>
 <result pre="in vitro diagnostics, when the human body reacts to an" exact="infectious" post="bio-stimulant [21]. Evaluation of Molecular RT-qPCR Tests that Detect"/>
 <result pre="The progress made in recent years in the diagnostics of" exact="infections" post="enables the application, often simultaneously, of numerous methods in"/>
 <result pre="application, often simultaneously, of numerous methods in order to detect" exact="respiratory" post="viruses effectively. The choice of suitable tests depends upon"/>
 <result pre="provide sets for extraction stages, and they need to be" exact="acquired" post="separately. However, all tests reviewed here that detect the"/>
 <result pre="the same micro-organisms. 3. Emerged Rapid Immunodiagnostic (Serology Immunoassays) Tests" exact="Immunological" post="methods are, most often, the chemiluminescent assaying of immunoglobulin"/>
 <result pre="due to the decreasing amount of virus particles in the" exact="respiratory" post="tract epithelium. In such cases, patients may have false"/>
 <result pre="provide the initial humoral response during the first stage of" exact="viral infection," post="prior to the onset of the adaptive, high-affinity IgG"/>
 <result pre="large family of viruses, which includes those causing Middle East" exact="Respiratory" post="Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), it"/>
 <result pre="family of viruses, which includes those causing Middle East Respiratory" exact="Syndrome" post="(MERS) and Severe Acute Respiratory Syndrome (SARS), it should"/>
 <result pre="which includes those causing Middle East Respiratory Syndrome (MERS) and" exact="Severe" post="Acute Respiratory Syndrome (SARS), it should be assumed that"/>
 <result pre="includes those causing Middle East Respiratory Syndrome (MERS) and Severe" exact="Acute" post="Respiratory Syndrome (SARS), it should be assumed that the"/>
 <result pre="those causing Middle East Respiratory Syndrome (MERS) and Severe Acute" exact="Respiratory" post="Syndrome (SARS), it should be assumed that the process"/>
 <result pre="causing Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory" exact="Syndrome" post="(SARS), it should be assumed that the process of"/>
 <result pre="result may be the evidence of past infection, not active" exact="infection" post="(Table 5). Negative results from serological tests do not"/>
 <result pre="results. This may be the case of past or ongoing" exact="infection" post="with virus strains other than SARS-CoV-2, such as coronavirus"/>
 <result pre="a material other than blood samples collected from patients, e.g.," exact="respiratory" post="tract secretions. Serological tests are thus applied as an"/>
 <result pre="less costly than genetic tests. This diagnostic method has a" exact="limited" post="sensitivity, yet efforts to improve it are ongoing, as"/>
 <result pre="data concerning, among others, the dynamics of immunological response to" exact="infection" post="and the diagnostic value of available tests for detecting"/>
 <result pre="cannot be used as a basic tool in diagnosing SARS-CoV-2" exact="infections" post="[32]. The detection of specific anti-SARS-CoV-2 antibodies is possible"/>
 <result pre="as it allows us to detect subjects who had the" exact="infection" post="but were asymptomatic or oligosymptomatic, and could have been"/>
 <result pre="asymptomatic or oligosymptomatic, and could have been the source of" exact="infection" post="for other people (â€œsilentâ€� carriers/vectors). It also allows us"/>
 <result pre="It also allows us to determine the spread of COVID-19" exact="infection" post="in the population. A comparative review of currently available"/>
 <result pre="serological immunodiagnostic COVID-19 tests is presented in Table 8. 3.3." exact="Protein" post="Microarray Method (PMM) The protein microarray method (PMM) is"/>
 <result pre="probe. The material captured may be antibodies, enzymes, or ligands." exact="Protein" post="analyte, added to the matrix, may be modified by"/>
 <result pre="of suitable equipment. The advantages of protein micromatrices include the" exact="short" post="time required for analysis, modest consumption of samples and"/>
 <result pre="protein micromatrices include the short time required for analysis, modest" exact="consumption" post="of samples and reagents, high sensitivity, automation of testing."/>
 <result pre="to serologically screen about 5000 individual peptides spanning the whole" exact="viral" post="proteome. Sequences of ORF1ab protein, surface glycoprotein, ORF3a protein,"/>
 <result pre="results and might support early implementation of isolation resources and" exact="infection" post="control measures. From a medical workforce point of view,"/>
 <result pre="of social distancing restrictions in future [30]. Moreover, with the" exact="limited" post="data available at present, for antibody-detecting and antigen-detecting rapid"/>
 <result pre="based on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas12a), with" exact="visual" post="readouts. The test can detect 10 copies of the"/>
 <result pre="novel diagnostic method, used mainly to assess inflammation within the" exact="respiratory" post="tract, and its components reflect the composition of the"/>
 <result pre="for the interpretation of serological POCTs. As with any other" exact="infectious diseases," post="the diagnostic value of a test is not only"/>
 <result pre="published version of the manuscript. Funding This study received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
 <result pre="of interest. References References 1.LauS.K.P.WooP.C.Y.YipC.C.Y.TseH.TsoiH.ChengV.C.C.LeeP.TangB.S.F.CheungC.H.Y.LeeR.A.et al.Coronavirus HKU1 and Other Coronavirus" exact="Infections" post="in Hong KongJ. Clin. Microbiol.2006442063207110.1128/JCM.02614-0516757599 2.SinghalT.A Review of Coronavirus"/>
 <result pre="online: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2.(accessed on 23 June 2020) 6.LuX.ChenY.BaiB.HuH.TaoL.YangJ.ChenJ.ChenZ.HuZ.WangH.Immune responses against severe" exact="acute" post="respiratory syndrome coronavirus induced by virus-like particles in miceImmunology200712249650210.1111/j.1365-2567.2007.02676.x17680799"/>
 <result pre="https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2.(accessed on 23 June 2020) 6.LuX.ChenY.BaiB.HuH.TaoL.YangJ.ChenJ.ChenZ.HuZ.WangH.Immune responses against severe acute" exact="respiratory" post="syndrome coronavirus induced by virus-like particles in miceImmunology200712249650210.1111/j.1365-2567.2007.02676.x17680799 7.LiuW.LiuL.KouG.ZhengY.DingY.NiW.WangQ.TanL.WuW.TangS.et"/>
 <result pre="on 23 June 2020) 6.LuX.ChenY.BaiB.HuH.TaoL.YangJ.ChenJ.ChenZ.HuZ.WangH.Immune responses against severe acute respiratory" exact="syndrome" post="coronavirus induced by virus-like particles in miceImmunology200712249650210.1111/j.1365-2567.2007.02676.x17680799 7.LiuW.LiuL.KouG.ZhengY.DingY.NiW.WangQ.TanL.WuW.TangS.et al.Evaluation"/>
 <result pre="23.HsuehP.R.HuangL.M.ChenP.J.KaoC.L.YangP.C.Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after" exact="infection" post="with SARS-associated coronavirusClin. Microbiol. Infect.2004101062106610.1111/j.1469-0691.2004.01009.x15606632 24.GuanM.ChenH.Y.FooS.Y.TanY.J.GohP.Y.WeeS.H.Recombinant protein-based enzyme-linked immunosorbent"/>
 <result pre="immunochromatographic tests for detection of immunoglobulin G antibodies to severe" exact="acute" post="respiratory syndrome (SARS) coronavirus in SARS patientsClin. Diagnost. Lab."/>
 <result pre="tests for detection of immunoglobulin G antibodies to severe acute" exact="respiratory" post="syndrome (SARS) coronavirus in SARS patientsClin. Diagnost. Lab. Immunol.20041128729110.1128/CDLI.11.2.287-291.2004"/>
 <result pre="for detection of immunoglobulin G antibodies to severe acute respiratory" exact="syndrome" post="(SARS) coronavirus in SARS patientsClin. Diagnost. Lab. Immunol.20041128729110.1128/CDLI.11.2.287-291.2004 25.KogakiH.UchidaY.FujiiN.KuranoY.MiyakeK.KidoY.KariwaH.TakashimaI.TamashiroH.LingA.-E.et"/>
 <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ. Med. Virol.202010.1002/jmv.2572732104917 31.Independent Evaluations of COVID-19 Serological TestsAvailable"/>
 <result pre="https://open.fda.gov/apis/device/covid19serology/(accessed on 13 June 2020) 32.LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.R.AzmanA.S.ReichN.G.LesslerJ.The Incubation Period of Coronavirus" exact="Disease" post="2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and"/>
 <result pre="Proteomics in multiplexNature200442910110710.1038/429101a15129287 34.HallD.A.PtacekJ.SnyderM.Protein microarray technologyMech. Ageing. Dev.200712816116710.1016/j.mad.2006.11.02117126887 35.ZhuH.HuS.JonaG.ZhuX.KreiswirthN.WilleyB.M.MazzulliT.LiuG.SongQ.ChenP.et al.Severe" exact="acute" post="respiratory syndrome diagnostics using a coronavirus protein microarrayProc. Natl."/>
 <result pre="in multiplexNature200442910110710.1038/429101a15129287 34.HallD.A.PtacekJ.SnyderM.Protein microarray technologyMech. Ageing. Dev.200712816116710.1016/j.mad.2006.11.02117126887 35.ZhuH.HuS.JonaG.ZhuX.KreiswirthN.WilleyB.M.MazzulliT.LiuG.SongQ.ChenP.et al.Severe acute" exact="respiratory" post="syndrome diagnostics using a coronavirus protein microarrayProc. Natl. Acad."/>
 <result pre="multiplexNature200442910110710.1038/429101a15129287 34.HallD.A.PtacekJ.SnyderM.Protein microarray technologyMech. Ageing. Dev.200712816116710.1016/j.mad.2006.11.02117126887 35.ZhuH.HuS.JonaG.ZhuX.KreiswirthN.WilleyB.M.MazzulliT.LiuG.SongQ.ChenP.et al.Severe acute respiratory" exact="syndrome" post="diagnostics using a coronavirus protein microarrayProc. Natl. Acad. Sci."/>
 <result pre="a coronavirus protein microarrayProc. Natl. Acad. Sci. USA20061034011401610.1073/pnas.051092110316537477 36.Molecular and" exact="Antibody" post="Point-Of-Care Tests to Support the Screening, Diagnosis and Monitoring"/>
 <result pre="gene Real Time PCR Kit CE-IVD Co-diagnostics Logix Smart Coronavirus" exact="disease" post="2019 CE-IVD CTK Biotech, Inc. Aridia COVID-19 Real Time"/>
 <result pre="Bio-Tech Liferiver Novel Coronavirus Multiplex RT-PCR CE-IVD, China FDA Thermo" exact="Fisher" post="TaqPathâ&quot;¢ COVID-19 CE-IVD RT-PCR Kit CE-IVD Automated Lab-based, near-POC"/>
 <result pre="test with respect to cross reactivity with other pathogens than" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (updated 13 June"/>
 <result pre="with respect to cross reactivity with other pathogens than Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (updated 13 June 2020,"/>
 <result pre="respect to cross reactivity with other pathogens than Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) (updated 13 June 2020, online"/>
 <result pre="to cross reactivity with other pathogens than Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) (updated 13 June 2020, online sources"/>
 <result pre="Kit CerTest Biotec, S.L VIASURE SARS-CoV-2 Co-diagnostics Logix Smart Coronavirus" exact="Disease" post="2019 Edinburgh Genetics COVID-19 Real-time PCR Testing Kit Liming"/>
 <result pre="nCoV Real-Time Detection Kit Seegene, Inc. Allplex 2019-nCoV Assay Thermo" exact="Fisher" post="Scientific TaqPath COVID-19 Combo Kit Abbott RealTime SARS-CoV-2 EUA"/>
 <result pre="nd - nd nd - - - - - -" exact="Respiratory" post="syncytial virus A nd - - - - -"/>
 <result pre="- - - - - - - - - -" exact="Respiratory" post="syncytial virus B nd - - - - -"/>
 <result pre="- - nd nd - - - - - -" exact="Legionella" post="pneumophila - - nd - - nd nd nd"/>
 <result pre="- nd nd nd - - - - - Mycobacterium" exact="tuberculosis" post="- nd nd - - nd nd nd -"/>
 <result pre="nd nd nd nd nd nd nd nd nd Bordetella" exact="pertussis" post="- - - - - nd nd nd -"/>
 <result pre="- nd nd - nd nd - nd - Human" exact="immunodeficiency" post="virus type 1,2 nd nd nd nd nd nd"/>
 <result pre="nd nd nd nd - nd nd nd nd nd" exact="Hepatitis" post="virus (A, B, C) nd nd nd nd nd"/>
 <result pre="often false negative, particularly during enhanced activity of the virus" exact="Simple" post="and comfortable to use and perform. Some tests may"/>
 <result pre="Small amount of material to be collected, variety of material." exact="Increased" post="risk of operator becoming infected â€œbest beforeâ€� date distant"/>
 <result pre="Clinical significance of an IgM/IgG serological test result. Phase of" exact="Infection" post="Type of Test PCR IgM IgG The window period"/>
 <result pre="window period for a test designed to detect a specific" exact="disease" post="P(+) N(âˆ’) N(âˆ’) Early stage of infection P(+) P(+)"/>
 <result pre="detect a specific disease P(+) N(âˆ’) N(âˆ’) Early stage of" exact="infection" post="P(+) P(+) N(âˆ’) Active phase of infection P(+) P(+)"/>
 <result pre="Early stage of infection P(+) P(+) N(âˆ’) Active phase of" exact="infection" post="P(+) P(+) P(+) Late or recurrent stage of infection"/>
 <result pre="N(âˆ’) Active phase of infection P(+) P(+) P(+) Late or" exact="recurrent" post="stage of infection P(+) N(âˆ’) P(+) Early stage of"/>
 <result pre="of infection P(+) P(+) P(+) Late or recurrent stage of" exact="infection" post="P(+) N(âˆ’) P(+) Early stage of infection. PCR result"/>
 <result pre="result may be false negative * N(âˆ’) P(+) N(âˆ’) Past" exact="infection" post="(recover) * N(âˆ’) N(âˆ’) P(+) The recovery stage of"/>
 <result pre="result may be false negative * N(âˆ’) P(+) P(+) No" exact="infection" post="and no special symptoms N(âˆ’) N(âˆ’) N(âˆ’) P(+)â€&quot;positive; N(âˆ’)â€&quot;negative."/>
 <result pre="false positive ELISA results. diagnostics-10-00434-t006_Table 6Table 6 Evaluations of Coronavirus" exact="Disease" post="2019 (COVID-19) serological tests, including sensitivity, specificity, and predictive"/>
 <result pre="Rapid Test kit PhamatechCOVID19 RAPID TEST Tianjin Beroni BiotechnologySARS-COV-2 IgG/IgM" exact="Antibody" post="Detection Kit Clinical Sensitivity IgM 100% 86.7% 26.7% 83.3%"/>
 <result pre="blood, serum or plasma 10â€&quot;15 BioMedomics, Inc COVID-19 IgM-IgG Dual" exact="Antibody" post="Rapid Test 89% 91% 10â€&quot;20 Î¼L whole blood, serum"/>
 <result pre="whole blood, serum or plasma 15â€&quot;20 Changsha Sinocare Inc. SARS-CoV-2" exact="Antibody" post="Test Strip (Colloidal Gold Method) 96.3% Serum/Plasma95.0% Whole blood"/>
 <result pre="99.4% 10â€&quot;15 Î¼L of serum or plasma 10â€&quot;15 Edinburgh Genetics" exact="Limited" post="Watmind 2019 nCoV novel coronavirus antibody detection reagent -"/>
 <result pre="Biotech, Inc. One Step Test for Novel Coronavirus (2019-nCoV) IgM/IgG" exact="Antibody" post="94.1% 95.1% 10 Î¼L of serum or plasma;20 Î¼L"/>
 <result pre="Kit - - - 15 InTec Products, Inc. Rapid SARS-CoV-2" exact="Antibody" post="Test IgG or Ig Mor IgG/IgM 94.4% 98% 10"/>
 <result pre="of whole blood 15 Livzon Diagnostic Diagnostic Kit for IgM/IgG" exact="Antibody" post="to Coronavirus (SARSCoV-2) 90.6% 99.2% 10 Î¼L of serum"/>
 <result pre="Î¼L whole blood 10 Sensing Self, COVID-19 Rapid IgG/IgM combined" exact="Antibody" post="assay IgM 92% IgG 100% IgM 97.58%IgG 99.31% 20"/>
 <result pre="blood, serum or plasma 15 Qingdao Hightop Biotech SARS-CoV-2 IgM/IgG" exact="Antibody" post="Rapid Test IgG 93%IgM 82% IgG 97.5%IgM 96% 10"/>
 <result pre="IgG/IgM Rapid Test Cassette CE-IVD BioMedomics, Inc COVID-19 IgM-IgG Dual" exact="Antibody" post="Rapid Test CE-IVD; India Cellex Inc. Cellex qSARS-CoV-2 IgG/IgM"/>
 <result pre="Rapid Test CE-IVD; USA; Australia; Brazil Changsha Sinocare Inc. SARS-CoV-2" exact="Antibody" post="Test Strip (Colloidal Gold Method) CE-IVD Edinburgh Genetics Limited"/>
 <result pre="SARS-CoV-2 Antibody Test Strip (Colloidal Gold Method) CE-IVD Edinburgh Genetics" exact="Limited" post="Watmind 2019 nCoV novel coronavirus antibody detection reagent CE-IVD"/>
 <result pre="Biotech, Inc. One Step Test for Novel Coronavirus (2019-nCoV) IgM/IgG" exact="Antibody" post="CE Goldsite Diagnostics Inc. SARS-CoV-2 IgG/IgM Kit - Hunan"/>
 <result pre="Gold) IgM/IgG CE-IVD; China, Brazil InTec Products, Inc. Rapid SARS-CoV-2" exact="Antibody" post="Test IgG or Ig Mor IgG/IgM CE-IVD Liming Bio-Products"/>
</results>
